

## Vtama® (tapinarof) - New indication

- On December 12, 2024, the <u>FDA approved</u> Dermavant Sciences' <u>Vtama (tapinarof)</u>, for the topical treatment of **atopic dermatitis in adults and pediatric patients 2 years of age and older**.
- Vtama is also approved for the topical treatment of plaque psoriasis in adults.
- The approval of Vtama for the new indication was based on two randomized, double-blind, vehicle-controlled studies in 813 adult and pediatric patients 2 years of age and older with atopic dermatitis (ADORING 1 and ADORING 2). Patients were randomized to Vtama or vehicle cream for 8 weeks. The primary efficacy endpoint in both studies was the proportion of subjects who achieved treatment success, defined as a vIGA-AD score of "Clear" (0) or "Almost Clear" (1) and at least a 2-grade improvement from baseline.
  - In ADORING 1, vIGA-AD was achieved in 45% and 14% of patients with Vtama and vehicle cream, respectively (treatment success difference 32, 95% CI: 23, 40).
  - In ADORING 2, vIGA-AD was achieved in 46% and 18% of patients with Vtama and vehicle cream, respectively (treatment success difference 29, 95% CI: 19, 38).
- The most common adverse reactions (≥ 1%) with Vtama use for atopic dermatitis were upper respiratory tract infection, **folliculitis**, lower respiratory tract infection, headache, asthma, vomiting, ear infection, pain in extremity, and abdominal pain.
- Vtama is administered as a thin layer applied topically to affected areas once daily.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.